4-methyl-4-(pyrrolidin-1-ylmethyl)oxazolidin-2-one | 1225437-76-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 4-methyl-4-(pyrrolidin-1-ylmethyl)oxazolidin-2-one
• 英文别名: 4-methyl-4-(pyrrolidin-1-ylmethyl)-1,3-oxazolidin-2-one
• CAS: 1225437-76-2
• 化学式: C₉H₁₆N₂O₂
• 分子量: 184.238
• InChiKey: WGXIYIHDXCNDMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-methyl-4-(pyrrolidin-1-ylmethyl)oxazolidin-2-one 在 次氯酸叔丁酯 作用下， 以 甲醇 为溶剂， 生成 1-((3-chloro-4-methyl-2-oxooxazolidin-4-yl)methyl)-1-methylpyrrolidinium chloride
  参考文献：
  名称：

  Novel 3-chlorooxazolidin-2-ones as antimicrobial agents

  摘要：

  Antimicrobial resistance against many known therapeutics is on the rise. We examined derivatives of 3-chlorooxazolidin-2-one 1a (X = H) as antibacterial and antifungal agents. The key findings were that the activity and apparent in vitro cytotoxicity could be controlled by the substitution of charged solubilizers at the 4- and 5-positions. These changes both significantly increase the antifungal potency and decrease cytotoxicity. Particularly effective were trialkylammonium groups which led to 400- to 600-fold increases in the antifungal therapeutic index when compared to their unsubstituted counterparts. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.036
• 作为产物：
  描述：

  四氢吡咯 、 N-((3-chloro-4-methyl-2-oxooxazolidin-4-yl)methyl)-N,N-dimethylpropan-1-aminium chloride 在 sodium iodide 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以35%的产率得到4-methyl-4-(pyrrolidin-1-ylmethyl)oxazolidin-2-one
  参考文献：
  名称：

  [EN] ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS
  [FR] COMPOSITIONS ANTIMICROBIENNES D'OXAZOLIDINONE, D'HYDANTOÏNE ET D'IMIDAZOLIDINONE

  摘要：

  本申请涉及Formula (I)中的N-氯代噁唑烷二酮、海因酮和咪唑烷二酮化合物，或其药用可接受的盐，以及相关的组合物和用作抗微生物剂的方法。

  公开号：

  WO2010054009A1

文献信息

• ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS
  申请人：Jain Rakesh K.

  公开号：US20100137349A1

  公开（公告）日：2010-06-03

  The present application relates to N-chlorinated oxazolidinone, hydantoin and imidazolidinone compounds of Formula I or pharmaceutically acceptable salts thereof, and associated compositions and methods of use as antimicrobial agents.

  本申请涉及公式I的N-氯代噁唑烷酮，脲和咪唑烷酮化合物或其药学上可接受的盐，以及相关的组合物和用作抗微生物剂的方法。
• Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions
  申请人：Jain Rakesh K.

  公开号：US08722715B2

  公开（公告）日：2014-05-13

  The present application relates to N-chlorinated oxazolidinone, hydantoin and imidazolidinone compounds of Formula I or pharmaceutically acceptable salts thereof, and associated compositions and methods of use as antimicrobial agents.

  本申请涉及公式I的N-氯代噁唑啉酮，恒二酸酐和咪唑啉酮化合物，或其药学上可接受的盐，以及相关的组合物和用作抗微生物剂的方法。
• US8722715B2
  申请人：——

  公开号：US8722715B2

  公开（公告）日：2014-05-13
• [EN] ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS<br/>[FR] COMPOSITIONS ANTIMICROBIENNES D'OXAZOLIDINONE, D'HYDANTOÏNE ET D'IMIDAZOLIDINONE
  申请人：NOVABAY PHARMACEUTICALS INC

  公开号：WO2010054009A1

  公开（公告）日：2010-05-14

  The present application relates to N-chlorinated oxazolidinone, hydantoin and imidazolidinone compounds of Formula (I): or pharmaceutically acceptable salts thereof, and associated compositions and methods of use as antimicrobial agents.

  本申请涉及Formula (I)中的N-氯代噁唑烷二酮、海因酮和咪唑烷二酮化合物，或其药用可接受的盐，以及相关的组合物和用作抗微生物剂的方法。
• Novel 3-chlorooxazolidin-2-ones as antimicrobial agents
  作者：Timothy P. Shiau、Eric D. Turtle、Charles Francavilla、Nichole J. Alvarez、Meghan Zuck、Lisa Friedman、Donogh J.R. O’Mahony、Eddy Low、Mark B. Anderson、Ramin (Ron) Najafi、Rakesh K. Jain

  DOI：10.1016/j.bmcl.2011.03.036

  日期：2011.5

  Antimicrobial resistance against many known therapeutics is on the rise. We examined derivatives of 3-chlorooxazolidin-2-one 1a (X = H) as antibacterial and antifungal agents. The key findings were that the activity and apparent in vitro cytotoxicity could be controlled by the substitution of charged solubilizers at the 4- and 5-positions. These changes both significantly increase the antifungal potency and decrease cytotoxicity. Particularly effective were trialkylammonium groups which led to 400- to 600-fold increases in the antifungal therapeutic index when compared to their unsubstituted counterparts. (C) 2011 Elsevier Ltd. All rights reserved.